Cell & Gene Therapy Insights feature: “Thinking ahead: developing biosynthetic blood to anticipate donor drought”
Co-Written by Andrew Spencer Goldman, RSV General Counsel and Head of Policy, Taylor Rose, RSV Global Access Fellow, and Luna Patel, RSV Volunteer.
How could viable biosynthetic blood technology radically transform the health outcomes of people around the world? How is biosynthetic blood different and a more promising option for patients than artificial blood? What investments are needed to push development to ensure sustainable, commercially viable, and equitable global access?
This week Cell & Gene Therapy Insights published, "Thinking ahead: developing biosynthetic blood to anticipate donor drought," co-written last fall by Andrew Spencer Goldman, Roivant Social Ventures (RSV) General Counsel and Head of Policy, and Taylor Rose, RSV Global Access Fellow.
"There is a tremendous global need to develop a sufficient, sustainable, and safe blood supply for a wide variety of medical needs...
Unfortunately, the 118.5 million pints of blood donated annually, with the inherent challenges of maintaining a secure blood supply, are insufficient to meet global need, particularly in low- and middle-income countries...
Fortunately, promising scientific research has shown success creating red blood cells (RBC) from human stem cells that mimic human donor blood, suggesting that there is a real possibility to develop an unlimited biosynthetic blood supply through creation of these biosynthetic RBCs..."
Read the full publication by clicking here.
This piece was also co-written by Shane Kilpatrick, Marinna Madrid, Zhong Ri Lim, Steve Oh, Lena Patel, and Barbara A Nelsen.